Predictors for Chemotherapy induced polyneuropathy identified with mass spectrometry

PRINCIPLE INVESTIGATORS:
PD Dr. Petra Hühnchen, Dr. Michael Mülleder, PD Dr. Wolfgang Böhmerle, Prof. Dr. Matthias Endres
Charité

SUMMARY
Neuropathies are among the most common side effects of cytotoxic chemotherapy. These impairments affect the quality of life and represent a dose-limiting factor for treatment of cancer patients. This project aims to identify and validate prognostic biomarkers: these will enable to predict chemotherapy induced polyneuropathies and prevent neurotoxicity by preselecting patients at risk.

PROJECT GOALS
- Identify and validate biomarker profile(s)
- Patent submission

LONG-TERM GOALS
- Clinical validation of biomarker set
- License to Biotech or start-up foundation